Efstathios Kastritis

Videos

Daratumumab Added to Standard Frontline AL Amyloidosis Treatment Demonstrates Improved Clinical Outcomes

01/15/2025

In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.

In the final analysis of the...

01/15/2025

Oncology

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

Erik G. Poulsen ;

10/23/2019

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Erik G. Poulsen ;

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

10/23/2019

Differential donor‐, cell type‐ and drug‐specific molecular responses to therapeutic proteasome inhibitors in Multiple Myeloma patients and cells

Introduction: Purpose of the study: Proteasome over‐activation represents a hallmark of several advanced tumors and thus, its selective inhibition provides a promising anti‐tumor the...

Ourania Tsitsilonis ;

Herman Overkleeft ;

Leonidas Alexopoulos ;

Ioannis Trougakos ;

Meletios-Athanasios Dimopoulos ;

Eleni-Dimitra Papanagnou ;

Efstathios Kastritis ;

Aikaterini Skorda ;

Aimilia Sklirou ;

Evangelos Terpos ;

10/22/2019